Recent chatter on X about Abbott Laboratories (ABT) has centered on the company’s third-quarter 2025 earnings report, which showed mixed results. Many users have pointed out the slight revenue miss, attributing it to weaker demand in diagnostics and nutritional segments, while others highlight the strength in medical device sales as a positive note. The stock’s subsequent dip has sparked debates about whether this presents a potential opportunity or signals deeper concerns.
Discussions also reflect on the company’s narrowed full-year guidance for 2025, with some expressing frustration over the lack of upside surprises in the numbers. A few voices on X remain optimistic, emphasizing the long-term growth potential in Abbott’s medtech portfolio despite short-term hiccups. The conversation continues to evolve as investors weigh the balance between temporary setbacks and sustained fundamentals.
Note: This discussion summary was generated from an AI condensation of post data.
Abbott Laboratories Congressional Stock Trading
Members of Congress have traded $ABT stock 8 times in the past 6 months. Of those trades, 3 have been purchases and 5 have been sales.
Here’s a breakdown of recent trading of $ABT stock by members of Congress over the last 6 months:
- REPRESENTATIVE RICK LARSEN purchased up to $15,000 on 10/06.
- REPRESENTATIVE JULIE JOHNSON sold up to $15,000 on 08/14.
- REPRESENTATIVE THOMAS H. KEAN, JR. purchased up to $15,000 on 07/21.
- REPRESENTATIVE JOSH GOTTHEIMER sold up to $15,000 on 07/18.
- REPRESENTATIVE LISA C. MCCLAIN has traded it 2 times. They made 1 purchase worth up to $15,000 on 06/24 and 1 sale worth up to $15,000 on 07/10.
- REPRESENTATIVE JEFFERSON SHREVE sold up to $100,000 on 05/12.
- REPRESENTATIVE BRUCE WESTERMAN sold up to $15,000 on 04/21.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
Abbott Laboratories Insider Trading Activity
Abbott Laboratories insiders have traded $ABT stock on the open market 2 times in the past 6 months. Of those trades, 0 have been purchases and 2 have been sales.
Here’s a breakdown of recent trading of $ABT stock by insiders over the last 6 months:
- PHILIP P BOUDREAU (EVP AND CFO) sold 5,550 shares for an estimated $746,758
- SALLY E. BLOUNT sold 2,600 shares for an estimated $337,116
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
Abbott Laboratories Hedge Fund Activity
We have seen 1,406 institutional investors add shares of Abbott Laboratories stock to their portfolio, and 1,376 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- CAPITAL RESEARCH GLOBAL INVESTORS removed 8,968,261 shares (-17.7%) from their portfolio in Q2 2025, for an estimated $1,219,773,178
- CAPITAL INTERNATIONAL INVESTORS removed 6,687,339 shares (-10.0%) from their portfolio in Q2 2025, for an estimated $909,544,977
- PRICE T ROWE ASSOCIATES INC /MD/ added 6,178,992 shares (+148.2%) to their portfolio in Q2 2025, for an estimated $840,404,701
- WELLINGTON MANAGEMENT GROUP LLP removed 4,712,836 shares (-15.8%) from their portfolio in Q2 2025, for an estimated $640,992,824
- BLACKROCK, INC. added 4,309,866 shares (+3.1%) to their portfolio in Q2 2025, for an estimated $586,184,874
- BOSTON PARTNERS removed 3,107,794 shares (-99.0%) from their portfolio in Q2 2025, for an estimated $422,691,061
- VANGUARD GROUP INC added 2,977,715 shares (+1.8%) to their portfolio in Q2 2025, for an estimated $404,999,017
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Abbott Laboratories Government Contracts
We have seen $86,209,736 of award payments to $ABT over the last year.
Here are some of the awards which we have have seen pay out the most over the last year:
- VISN 9 CHEMISTRY AUTOMATION COST PER RESULTS REPORTABLE: $4,510,608
- CHEMISTRY IMMUNOASSAY ANALYZER COST PER REPORTABLE RESULT (CPRR): $4,000,483
- LAB CHEMISTRY SERVICES: $3,766,564
- CIVILIAN DRUG FREE WORKPLACE COLLECTIONS AND MEDICAL REVIEW OFFICER SUPPORT SERVICES: $2,787,929
- EXERCISING OPTION YEAR 2: $2,600,297
To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard.
Abbott Laboratories Analyst Ratings
Wall Street analysts have issued reports on $ABT in the last several months. We have seen 7 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Evercore ISI Group issued a "Outperform" rating on 10/16/2025
- RBC Capital issued a "Outperform" rating on 10/16/2025
- Wells Fargo issued a "Overweight" rating on 10/16/2025
- Raymond James issued a "Outperform" rating on 10/16/2025
- BTIG issued a "Buy" rating on 10/15/2025
- Benchmark issued a "Buy" rating on 10/10/2025
- Jefferies issued a "Buy" rating on 07/18/2025
To track analyst ratings and price targets for Abbott Laboratories, check out Quiver Quantitative's $ABT forecast page.
Abbott Laboratories Price Targets
Multiple analysts have issued price targets for $ABT recently. We have seen 9 analysts offer price targets for $ABT in the last 6 months, with a median target of $145.0.
Here are some recent targets:
- Shagun Singh from RBC Capital set a target price of $147.0 on 10/16/2025
- Jayson Bedford from Raymond James set a target price of $146.0 on 10/16/2025
- Lawrence Biegelsen from Wells Fargo set a target price of $146.0 on 10/16/2025
- Vijay Kumar from Evercore ISI Group set a target price of $142.0 on 10/16/2025
- Marie Thibault from BTIG set a target price of $145.0 on 10/15/2025
- Bruce Jackson from Benchmark set a target price of $145.0 on 10/10/2025
- Anthony Petrone from Mizuho set a target price of $135.0 on 07/18/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.